诚达药业持股5%以上股东拟减持不超1100.69万股

Core Viewpoint - Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its shareholding in Chengda Pharmaceutical by up to 11,006,897 shares, representing 7.27% of the company's total share capital after excluding repurchased shares, within a three-month period starting from September 29, 2025 [1][2]. Shareholder Information - Shenzhen Qianhai Shengtai holds 11,006,897 shares, accounting for 7.27% of the total share capital, and the total share capital of the company is 154,713,824 shares, with 151,469,124 shares after excluding repurchased shares [2]. - The reduction is due to the shareholder's operational needs, and the shares were acquired prior to the company's initial public offering and through capital reserve conversion [2]. Reduction Plan Details - The reduction will occur through centralized bidding or block trading, with a planned period from September 29, 2025, to December 28, 2025 [1][2]. - The reduction price will be determined based on market conditions, and adjustments will be made if there are changes in share capital during the reduction period [2]. Shareholder Commitment - The shareholder has provided commitments regarding the lock-up of shares and intentions for reduction, with no reductions made during the lock-up period [3].